NASDAQ$TGTX
TG Therapeutics Inc. · Q4 2019 earnings
Q4 2019 earnings · · Investor relations
Briefing
TG Therapeutics reported financial results for Q4 and year ended December 31, 2019, along with business updates and outlook for 2020.
TG Therapeutics reported a net loss of $39.6 million for the fourth quarter of 2019. The company's cash, cash equivalents, and investment securities totaled $140.4 million as of December 31, 2019, expected to fund operations well into 2021. Key objectives for 2020 include reporting topline PFS results from the Phase 3 UNITY-CLL trial and completing the rolling NDA submission for umbralisib in patients with previously treated MZL and FL.
- Reported positive outcomes for umbralisib in both previously treated marginal zone lymphoma and follicular lymphoma from the UNITY-NHL trial.
- Commenced a single rolling submission with the FDA based on UNITY-NHL trial data.
- Awaiting topline results from Phase 3 programs in CLL and MS.
- Potentially first FDA approval around year-end.
Headline financials
Revenue & EPS history
TG Therapeutics · Revenue · Quarterly
$38K
Forward guidance
TG Therapeutics anticipates several key milestones in 2020, including data readouts and regulatory submissions.
Tailwinds
- Report topline PFS results from the Phase 3 UNITY-CLL trial evaluating U2 in patients with frontline and previously treated CLL.
- Target a potential New Drug Application (NDA)/Biologics Licensing Application (BLA) submission by year-end if UNITY-CLL trial is successful.
- Complete rolling NDA submission for umbralisib in patients with previously treated MZL and FL in the first half of 2020.
- Report topline results from the Phase 3 ULTIMATE I & II trials in RMS in the second half of 2020.
- Continue to advance early pipeline candidates including TG-1501 (cosibelimab), TG-1701 and TG-1801.
Headwinds
- The risk that the interim data from the UNITY-NHL MZL cohort will not be reproduced when the final analysis is conducted on all patients.
- The risk that the final analysis of the UNITY-NHL MZL or FL cohorts will be insufficient to support a filing for accelerated approval.
- The risk that umbralisib will not receive accelerated approval based on data from the UNITY-NHL MZL or FL cohorts.
- The risk that PFS data from UNITY-CLL will not be positive or, if positive, will not be accepted for filing by the FDA.
- The risk that the anticipated timeline for completing the submission of the umbralisib NDA in MZL and FL based on the UNITY NHL data will be delayed.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2019
+2.7%
Avg return
Earnings day
+5.5%
Avg return
5 days after
+4.1%
Avg return
30 days after
49%
27 / 55 earnings
Positive
+81.0%
Q3 2022
Best reaction
-49.0%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +16.3% | +19.4% | +11.1% | |
| Q4 2025 | +4.3% | -2.6% | +7.0% | |
| Q3 2025 | -1.0% | -7.3% | -9.1% | |
| Q1 2025 | -13.4% | -22.6% | -14.7% | |
| Q4 2024 | +14.4% | +27.8% | +32.3% | |
| Q3 2024 | -3.9% | +7.1% | +25.9% | |
| Q2 2024 | +16.2% | +15.7% | +24.7% | |
| Q1 2024 | +20.2% | +20.9% | +19.3% | |
| Q4 2023 | +23.8% | +28.5% | +9.3% | |
| Q3 2023 | +34.7% | +32.6% | +78.9% | |
| Q2 2023 | -49.0% | -48.2% | -49.4% | |
| Q1 2023 | +25.5% | +38.1% | +7.2% | |
| Q4 2022 | -3.8% | +7.8% | -8.2% | |
| Q3 2022 | +81.0% | +70.7% | +45.7% | |
| Q2 2022 | +19.4% | +33.4% | +9.1% | |
| Q1 2022 | -10.9% | +1.4% | -24.5% | |
| Q4 2021 | +4.7% | -11.1% | -3.6% | |
| Q3 2021 | +7.9% | +5.3% | -52.5% | |
| Q2 2021 | -27.2% | -32.8% | -15.8% | |
| Q1 2021 | -6.7% | -14.8% | -7.2% | |
| Q4 2020 | -5.0% | -3.8% | +8.8% | |
| Q3 2020 | -0.2% | +4.4% | +5.0% | |
| Q2 2020 | -12.0% | +2.6% | +22.3% | |
| Q1 2020 | +5.9% | +2.6% | -6.0% | |
| Q4 2019 | -4.1% | -13.6% | -32.6% | |
| Q3 2019 | +1.4% | +2.7% | +20.6% | |
| Q2 2019 | +3.3% | +0.1% | -8.4% | |
| Q1 2019 | -15.5% | -13.4% | -8.0% | |
| Q4 2018 | +0.4% | -8.1% | +18.2% | |
| Q3 2018 | +2.5% | -1.1% | -4.4% | |
| Q2 2018 | -3.4% | -0.4% | +0.0% | |
| Q1 2018 | -3.7% | -2.6% | +3.7% | |
| Q4 2017 | +8.5% | +10.2% | -15.1% | |
| Q3 2017 | +9.9% | +9.3% | +12.6% | |
| Q2 2017 | +1.0% | +16.0% | +22.0% | |
| Q1 2017 | +2.5% | +11.3% | +36.5% | |
| Q4 2016 | +3.4% | +22.5% | -10.6% | |
| Q3 2016 | +1.0% | +6.7% | -1.9% | |
| Q2 2016 | -7.6% | -0.2% | +13.3% | |
| Q1 2016 | -1.4% | — | — | |
| Q4 2015 | -6.8% | — | — | |
| Q3 2015 | +8.4% | — | — | |
| Q2 2015 | -2.2% | — | — | |
| Q1 2015 | -6.0% | — | — | |
| Q3 2014 | +14.6% | — | — | |
| Q1 2012 | -3.7% | — | — | |
| Q2 2012 | -14.3% | — | — | |
| Q4 2011 | -23.0% | — | — | |
| Q3 2011 | +0.0% | — | — | |
| Q2 2011 | +0.0% | — | — | |
| Q1 2011 | +36.4% | — | — | |
| Q4 2010 | +7.7% | — | — | |
| Q3 2010 | +0.0% | — | — | |
| Q2 2010 | +0.0% | — | — | |
| Q1 2010 | +0.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro